We report the case of a healthcare worker who presented with a large vessel acute ischemic stroke in setting of a mild SARS-CoV-2 infection and provide a review of the emerging literature on COVID-related stroke. A 43-year-old female presented with right-sided hemiparesis, aphasia and dysarthria. She had a nonproductive of cough for 1 week without fever, fatigue or dyspnea. A CT Head, CT angiography and CT perfusion imaging revealed a M1 segment occlusion of the left middle cerebral artery requiring transfer from a primary to a comprehensive stroke center. A nasopharyngeal swab confirmed SARS-CoV-2 infection prior to arrival at the accepting center. During the thrombectomy a 3 cm thrombus was removed. Thrombus was also evident in the 8 French short sheath during closure device placement so a hypercoagulable state was suspected. Stroke work-up revealed a glycosylated hemoglobin of 8.7%, elevation of inflammatory markers and an indeterminate level of lupus anticoagulant IgM. On discharge home, she had near complete neurological recovery.
This case highlights suspected mechanisms of hypercoagulability in SARS-CoV-2 infection and the importance of optimizing stroke care systems during the COVID-19 pandemic.
ZhouFYuTDuR, et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
3.
PanigadaMBottinoNTagliabueP, et al.Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020;18(7):1738–1742
4.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587.
5.
HackeWKasteMFieschiC, et al.Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017–1025.
6.
HackeWKasteMFieschiC, et al.Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet (London, England). 1998;352(9136):1245–1251.
7.
Multicenter Acute Stroke Trial--Europe Study Group, HommelMCornuCBoutitieFBoisselJP. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335(3):145–150.
8.
LarrueVvon KummerRdel ZoppoGBluhmkiE. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28(5):957–960.
9.
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA stroke study group. Stroke. 1997;28(11):2109–2118.
10.
NguyenLHDrewDAGrahamMS, et al.Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5(9):e475–e483.
11.
DaferRMOsteraasNDBillerJ. Acute stroke care in the coronavirus disease 2019 pandemic. J Stroke Cerebrovasc Dis. 2020;29(7):104881.
12.
AHA/ASA Stroke Council Leadership. Temporary emergency guidance to US stroke centers during the COVID-19 pandemic. Stroke. 2020;51(6):1910–1912.
13.
LiYLiMWangM, et al.Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3):279–284.
14.
MaoLJinHWangM, et al.Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology. 2020;77(6):683–690.
15.
HelmsJKremerSMerdjiH, et al.Neurologic features in severe SARS-CoV-2 infection. N Engl J Med .2020;382(23):2268–2270.
16.
LodigianiCIapichinoGCarenzoL, et al.Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
17.
KlokFAKruipMvan der MeerNJM, et al.Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147
18.
KihiraSScheffleinJMahmoudiK, et al.Association of Coronavirus Disease (COVID-19) with large vessel occlusion strokes: a case-control study. AJR Am J Roentgenol. 2020:1–6.
19.
AltschulDJEsenwaCHaranhalliN, et al.Predictors of mortality for patients with COVID-19 and large vessel occlusion. Interv Neuroradiol. 2020;26(5):622–627.
20.
AvulaANalleballeKNarulaN, et al.COVID-19 presenting as stroke. Brain Behav Immun. 2020;87:115–119.
21.
EscalardSMaïerBRedjemH, et al.Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke. 2020;51(8):2540–2543.
22.
MajidiSFifiJTLadnerTR, et al.Emergent large vessel occlusion stroke during New York City’s COVID-19 outbreak: clinical characteristics and paraclinical findings. Stroke. 2020;51(9):2656–2663.
23.
MerklerAEParikhNSMirS, et al.Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs Patients With Influenza [published online ahead of print, 2020 Jul 2]. JAMA Neurol. 2020;e202730.
24.
OxleyTJMoccoJMajidiS, et al.Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Medicine. 2020;328(20):e60.
25.
PopRHasiuABologniniF, et al.Stroke thrombectomy in patients with COVID-19: Initial experience in 13 cases [published online ahead of print, 2020 Aug 13]. AJNR Am J Neuroradiol. 2020;10.3174/ajnr.A6750.
26.
RothsteinAOldridgeOSchwennesenHDoDCucchiaraBL. Acute cerebrovascular events in hospitalized COVID-19 patients. Stroke. 2020;51(9):e219–e222.
27.
SieglerJECardonaPArenillasJF, et al.EXPRESS: cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 Multinational Registry. Int J Stroke. 2020. doi:10.1177/1747493020959216
28.
SweidAHammoudBBekelisK, et al.Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019. Int J Stroke. 2020;15(7):733–742.
29.
WangAMandigoGKYimPDMeyersPMLavineSD. Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. J Neurointerv Surg. 2020;12(7):648–653.
30.
YaghiSIshidaKTorresJ, et al.SARS-CoV-2 and Stroke in a New York Healthcare System. Stroke. 2020;51(7):2002–2011.
31.
TanYKGohCLeowAST, et al.COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis. 2020;50(3):587–595.
32.
FridmanSBullrichMBJimenez-RuizA, et al.Stroke Risk, phenotypes, and death in COVID-19: Systematic review and newly reported cases. [published online ahead of print, 2020 Sep 15]. Neurology. 2020;10.1212/WNL
33.
UmapathiTKorACVenketasubramanianN, et al.Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227–1231.
34.
VargaZFlammerAJSteigerP, et al.Endothelial cell infection and endotheliitis in COVID-19. Lancet (London, England). 2020;395(10234):1417–1418.
35.
ZhangYXiaoMZhangS, et al.Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.
36.
WangDHuBHuC, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
37.
KochavSMCoromilasENalbandianA, et al.Cardiac arrhythmias in COVID-19 infection. Circ Arrhythm Electrophysiol. 2020;13(6):e008719.
38.
PuntmannVOCarerjMLWietersI, et al.Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) [published online ahead of print, 2020 Jul 27]. JAMA Cardiol. 2020;e203557.
39.
NagelMAMahalingamRCohrsRJGildenD. Virus vasculopathy and stroke: an under-recognized cause and treatment target. Infect Disord Drug Targets. 2010;10(2):105–111.
